TY - JOUR
T1 - Convalescent Plasma to Treat COVID-19
T2 - A Two-Center, Randomized, Double-Blind Clinical Trial
AU - Ventura-Enríquez, Yanet
AU - Cabello-Gutiérrez, Carlos
AU - Pérez-Calatayud, Ángel Augusto
AU - Cortina-De la Rosa, Evelyn
AU - Fareli-González, Christian Javier
AU - Castillo-Juárez, Paola
AU - Carlos, Alberto Peña Pérez
AU - Zavaleta-Martínez, Elí Omar
AU - Diaz-Padilla, Elizabeth
AU - Murrieta, Sandra
AU - Álvarez-Jiménez, Violeta Deyanira
AU - Ponce-Medrano, Juan Alberto Díaz
AU - Casillas-Suárez, Catalina
AU - Ocampo-Ocampo, María Angelica
AU - Vargas-De-León, Cruz
AU - Fernández-Sánchez, Verónica
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/11
Y1 - 2022/11
N2 - Background: The use of convalescent plasma (CP) has been considered for its immunological mechanisms that could benefit patients in moderate and severe stages of COVID-19. This study evaluated the safety and efficacy of the use of donor CP for COVID-19. Material and methods: A double-blind, randomized controlled clinical trial was conducted from May to October 2020. Thirty-nine participants with moderate (II) and severe (III) stages of COVID-19 confirmed by RT-PCR were included. The study randomization rate was set at 3:1. CPs were chosen for application with a neutralizing antibody titer of ≥1:32. Results: We observed a significantly lower 21-day post-transfusion mortality HR: 0.17 (95.0% CI [0.07–0.45, p < 0.001]) in the group receiving CP compared with the control group; protective units (PU) in the group receiving convalescent plasma after seven days were significantly higher (512 (32–16,384) vs. 96 (32–256), p = 0.01); the PAO2/FIO2 index showed a significant improvement in the group receiving CP (251.01 (109.4) vs. 109.2 (62.4), p < 0.001, in the control group). Conclusion: CP is safe and effective, as it decreased mortality in the CP group compared with the control group.
AB - Background: The use of convalescent plasma (CP) has been considered for its immunological mechanisms that could benefit patients in moderate and severe stages of COVID-19. This study evaluated the safety and efficacy of the use of donor CP for COVID-19. Material and methods: A double-blind, randomized controlled clinical trial was conducted from May to October 2020. Thirty-nine participants with moderate (II) and severe (III) stages of COVID-19 confirmed by RT-PCR were included. The study randomization rate was set at 3:1. CPs were chosen for application with a neutralizing antibody titer of ≥1:32. Results: We observed a significantly lower 21-day post-transfusion mortality HR: 0.17 (95.0% CI [0.07–0.45, p < 0.001]) in the group receiving CP compared with the control group; protective units (PU) in the group receiving convalescent plasma after seven days were significantly higher (512 (32–16,384) vs. 96 (32–256), p = 0.01); the PAO2/FIO2 index showed a significant improvement in the group receiving CP (251.01 (109.4) vs. 109.2 (62.4), p < 0.001, in the control group). Conclusion: CP is safe and effective, as it decreased mortality in the CP group compared with the control group.
KW - COVID-19
KW - SARS-CoV-2
KW - convalescent plasma treatment
KW - neutralizing antibodies
UR - http://www.scopus.com/inward/record.url?scp=85141690396&partnerID=8YFLogxK
U2 - 10.3390/life12111767
DO - 10.3390/life12111767
M3 - Artículo
C2 - 36362922
AN - SCOPUS:85141690396
SN - 2075-1729
VL - 12
JO - Life
JF - Life
IS - 11
M1 - 1767
ER -